ClinicalTrials.gg
CompletedNCT06708416Updated Jul 15, 2026

A Study of ONO-1110 in Patients With Postherpetic Neuralgia

A Phase 2 interventional study of ONO-1110 and Placebo in Postherpetic Neuralgia, sponsored by Ono Pharmaceutical Co., Ltd.. Completed at 31 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Neuralgia, Postherpetic with a site in Japan — none open to participants now, none under way, none of them phase 3. Neuralgia, Postherpetic · Japan.

Enrollment
5th of 10
142 · median 136
Started
2025
the only one that year
Phase 2
5 of 11
none open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Ono Pharmaceutical Co., Ltd.

Among the 11 studies in Neuralgia, Postherpetic with a site in Japan, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 5 in phase 2, and was the 11th registered.

Neuralgia, Postherpetic

197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.

Browse Neuralgia, Postherpetic studies →

Open to participants now

None of the 11 studies in Neuralgia, Postherpetic with a site in Japan is open now. The open studies under Neuralgia, Postherpetic, anywhere →

Who these studies take

Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Neuralgia, Postherpetic with a site in Japan as a file.
02

Study summary

To evaluate the efficacy and safety of ONO-1110 in Japanese patients with postherpetic neuralgia

03

Conditions studied

  • Postherpetic Neuralgia

Keywords

  • ONO-1110
  • ONO-1110-04
  • Postherpetic Neuralgia
  • PHN
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese (both sexes)
  • Age (at the time of ): 18 years and older
  • Outpatient
  • Patients with persistent pain ≥3 months (90 days) after the onset of herpes zoster
  • Patients who are considered capable of understanding the study procedures and completing the pain diary and questionnaires appropriately by the investigator (sub-investigator)

Exclusion criteria

Exclusion Criteria:

  • Patients who previously underwent neurodestruction or neurosurgical therapy for PHN
  • Patients with pain other than PHN that may affect assessments in this study
  • Patients with any skin condition related to the site of herpes zoster that may affect assessments in this study
  • Patients with a past history of or concurrent neurologic diseases that may affect assessments in this study
  • Patients with concurrent psychiatric diseases that may affect assessments in this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    ONO-1110

    ONO-1110 tablets once a day

    Drug: ONO-1110

  • Placebo comparator
    Placebo

    Placebo tablets once daily

    Drug: Placebo

Interventions

  • ONO-1110 tablets once a day

  • DrugPlacebo

    Placebo tablets once daily

06

What researchers measure

Primary outcomes

  1. Change in weekly mean of average pain score (last 7-day mean of past 24-hour average pain scores [NRS] in the pain diary) from baseline to Week 8 of the treatment period

    Time frame: Up to 15 weeks

  2. Adverse Events

    Time frame: Up to 15 weeks

Secondary outcomes

  1. Change in weekly mean of average pain score from baseline to each week

    Time frame: Up to 15 weeks

  2. 30%- and 50%-responder rates based on the weekly mean of average pain score (proportions of participants whose weekly mean of average pain score has decreased by 30% and 50% from baseline, respectively)

    Time frame: Up to 15 weeks

  3. Change in weekly mean of worst pain score (last 7-day mean of past 24-hour worst pain scores [NRS] in the pain diary) from baseline to each week

    Time frame: Up to 15 weeks

  4. 30%- and 50%-responder rates based on the weekly mean of worst pain score (proportions of participants whose weekly mean of worst pain score has decreased by 30% and 50% from baseline, respectively)

    Time frame: Up to 15 weeks

  5. Change in Brief pain inventory-short form (BPI-SF) score from baseline

    Time frame: Up to 15 weeks

  6. Change in Short Form McGill Pain Questionnaire-2 (SF-MPQ-2) score from baseline

    Time frame: Up to 15 weeks

  7. Patient Global Impression of Change (PGIC) score

    Time frame: Up to 15 weeks

  8. Change in Hospital Anxiety and Depression Scale (HADS) score from baseline

    Time frame: Up to 15 weeks

  9. Plasma ONO-1110 concentrations

    Time frame: Up to 15 weeks

07

Study locations

31 sites
  • Kamezawa Clinic
    Aichi, Japan
  • Kimura Clinic
    Aichi, Japan
  • Fukuoka Tokushukai Hospital
    Fukuoka, Japan
  • Southern Tohoku General Hospital
    Fukushima, Japan
  • Central Japan International Medical Center
    Gifu, Japan
  • National Hospital Organization Kure Medical Center
    Hiroshima, Japan
  • National Hospital Organization Hokkaido Medical Center
    Hokkaido, Japan
  • Nishinomiya Municipal Central Hospital
    Hyōgo, Japan
  • Mito Saiseikai General Hospital
    Ibaraki, Japan
  • Kawasaki Municipal Hospital
    Kanagawa, Japan
  • Konan Hidamari Pain Clinic
    Kanagawa, Japan
  • Nomura Dermatology Clinic
    Kanagawa, Japan
  • Tai Clinic
    Kanagawa, Japan
  • Yokohama City Minato Red Cross Hospital
    Kanagawa, Japan
  • Junwakai Memorial Hospital
    Miyazaki, Japan
  • Medical Corporation Toyama Dermatology
    Miyazaki, Japan
  • Yuaikai Tomishiro Chuo Hospital
    Okinawa, Japan
  • Morimoto Clinic
    Osaka, Japan
  • Osaka Medical and Pharmaceutical University Hospital
    Osaka, Japan
  • Osaka Metropolitan University Hospital
    Osaka, Japan
  • Medical Corporation Fujigaki Clinic
    Ōita, Japan
  • Chutoen General Medical Center
    Shizuoka, Japan
  • Shizuoka Rehabili Pain Clinic
    Shizuoka, Japan
  • Fukuuchi Pain Clinic
    Tokyo, Japan
  • Fukuwa Clinic
    Tokyo, Japan
  • Futaki Skin Care Clinic
    Tokyo, Japan
  • Juntendo University Hospital
    Tokyo, Japan
  • Mitaka Pain Clinic
    Tokyo, Japan
  • Nishiogi Pain Clinic
    Tokyo, Japan
  • Tokyo-Eki Center-Building Clinic
    Tokyo, Japan
  • Yamanashi Prefectural Central Hospital
    Yamanashi, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in May 2026, 14 months.

Of 12 phase 2 interventional studies under Neuralgia, Postherpetic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 14 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2024
First posted
Nov 27, 2024
StartActual
Feb 12, 2025
Primary completionActual
May 11, 2026
CompletionActual
May 11, 2026
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06708416
Responsible party
Sponsor
First posted
Nov 27, 2024
Start date
Feb 12, 2025
Primary completion
May 11, 2026
Completion
May 11, 2026
Last update
Jul 15, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ONO-1110

Start the discussion